Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AGN201781 in Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of postherpetic neuralgia or post-traumatic peripheral neuralgia~* Moderate or severe pain associated with postherpetic neuralgia or post-traumatic peripheral neuralgia~Exclusion Criteria:~* Women of child-bearing potential~* Any other uncontrolled diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- AGN201781 (Type: EXPERIMENTAL): AGN201781 50 mg capsules three-time daily for 2 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo 50 mg capsules three-times daily for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).